A Double-Blind Efficacy and Safety Study of the Phosphodiesterase Type 5 Inhibitor Tadalafil in Pediatric Patients With Pulmonary Arterial Hypertension

Trial Profile

A Double-Blind Efficacy and Safety Study of the Phosphodiesterase Type 5 Inhibitor Tadalafil in Pediatric Patients With Pulmonary Arterial Hypertension

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Tadalafil (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 18 Aug 2016 Planned End Date changed from 1 Dec 2022 to 1 Jan 2023.
    • 18 Aug 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jan 2021.
    • 05 Sep 2014 Planned End Date changed from 1 Jul 2021 to 1 Dec 2022 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top